Valneva SE - Company Profile

Powered by

All the data and insights you need on Valneva SE in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Valneva SE Strategy Report

  • Understand Valneva SE position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Valneva SE: Overview

Select Item

Related keylists

Valneva SE (Valneva) is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of Lyme disease, Zika virus, Chikungunya and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and distribute its products. The company sells its products in the Americas, Asia-Pacific, Europe, and the Middle East. It operates in Austria, Sweden, the UK, France, the US, and Canada. Valneva is headquartered in Saint-Herblain, France.

 Gain a 360-degree view of Valneva SE and make more informed decisions for your business Gain a 360-degree view of Valneva SE and make more informed decisions for your business Find out more
Headquarters France
Address 6 Rue Alain Bombard, Saint-Herblain, Lorraine, 44800
Website valneva.com
Telephone 33 2 28073710
No of Employees 684
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange VLA (EPA)
Revenue (2022) $166.2M -57.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 29.2% (2022 vs 2021)
Market Cap* $593.7M
Net Profit Margin (2022) XYZ -66.4% (2022 vs 2021)
* As of and is in US$
View Valneva SE financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Valneva SE premium industry data and analytics

100+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Valneva SE’s relevant decision makers and contact details.

70+

Clinical Trials

Determine Valneva SE go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

60+

Catalyst Calendar

Proactively evaluate Valneva SE’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Pipeline Drugs

Identify which of Valneva SE’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

7

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Sales & Consensus Forecasts

Understand the current and future drug revenue for Valneva SE and assess market opportunity for new entrants with patient population 8-year forecasts.

3

Marketed Drugs

Understand Valneva SE’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Valneva SE’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Ixiaro/Jespect- Japanese Encephalitis Vaccine Distribution Services for Third-Party's Products IXIARO/JESPECT
Dukoral- Cholera Vaccine DUKORAL
Pipeline JEVAL
XYZ
XYZ
XYZ
Understand Valneva SE portfolio and identify potential areas for collaboration Understand Valneva SE portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Others In March, the company began the Phase I VLA1601-102 clinical trial of its second-generation adjuvanted inactivated vaccine candidate, VLA1601, against the Zika virus.
2023 Contracts/Agreements In August, the company entered into an agreement with funds managed by Deerfield Management Company and OrbiMed to increase the principal amount of US$100 million.
2022 Contracts/Agreements In September, the company and VBI Vaccines Inc entered into a partnership for the marketing and distribution of PreHevbri.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Valneva SE Astellas Pharma Inc bioMerieux SA Dynavax Technologies Corp Innate Pharma SA
Headquarters France Japan France United States of America France
City Saint-Herblain Chuo-Ku Craponne Emeryville Marseille
State/Province Lorraine Tokyo Rhone Alpes California Bourgogne
No. of Employees 684 14,484 14,651 408 179
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Thomas Lingelbach President; Chief Executive Officer Executive Board 2013 59
Franck Grimaud Director - General; Chief Business Officer Executive Board 2013 56
Peter Buhler Chief Financial Officer Senior Management 2022 -
Juan Carlos Jaramillo, M.D. Chief Medical Officer Senior Management 2020 52
Dipal Patel Chief Commercial Officer Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Valneva SE key executives to enhance your sales strategy Gain insight into Valneva SE key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward